首页>
外国专利>
USE OF INACTIVATED NONREPLICATING MODIFIED VACCINIA VIRUS ANKARA (MVA) AS MONOIMMUNOTHERAPY OR IN COMBINATION WITH IMMUME CHECKPOINT BLOCKING AGENTS FOR SOLID TUMORS
USE OF INACTIVATED NONREPLICATING MODIFIED VACCINIA VIRUS ANKARA (MVA) AS MONOIMMUNOTHERAPY OR IN COMBINATION WITH IMMUME CHECKPOINT BLOCKING AGENTS FOR SOLID TUMORS
展开▼
机译:灭活的非复制型痘苗病毒安卡拉(MVA)作为单抗疗法或与免疫检查点阻断剂结合用于固体肿瘤
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present disclosure relates to infection-competent, but nonreplicative inactivated modified vaccinia Ankara (MVA) and its use as immunotherapy, alone, or in combination with immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to inducing an immune response in a subject diagnosed with a solid malignant tumor.
展开▼